Merit Medical Systems (NASDAQ:MMSI) Given New $101.00 Price Target at Needham & Company LLC

Merit Medical Systems (NASDAQ:MMSI) had its price target lifted by Needham & Company LLC from $90.00 to $101.00 in a research note released on Friday, MarketBeat.com reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other research analysts also recently weighed in on MMSI. Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a research note on Monday, April 20th. Wall Street Zen downgraded Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Wells Fargo & Company dropped their price objective on Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a report on Friday, May 1st. Piper Sandler reissued an “overweight” rating on shares of Merit Medical Systems in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. reduced their target price on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.30.

Merit Medical Systems Trading Up 2.0%

Shares of NASDAQ MMSI opened at $85.01 on Friday. The company’s 50 day simple moving average is $69.87 and its 200 day simple moving average is $71.78. Merit Medical Systems has a fifty-two week low of $59.74 and a fifty-two week high of $94.75. The firm has a market capitalization of $5.07 billion, a P/E ratio of 35.13, a P/E/G ratio of 2.59 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46.

Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.97%. The firm had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. During the same period last year, the firm earned $1.01 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. On average, analysts predict that Merit Medical Systems will post 3.62 EPS for the current year.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, insider Brian G. Lloyd bought 2,000 shares of Merit Medical Systems stock in a transaction on Thursday, May 7th. The shares were purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the acquisition, the insider owned 2,000 shares in the company, valued at approximately $125,240. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $62.61, for a total value of $313,050.00. Following the completion of the transaction, the director directly owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors have recently modified their holdings of the business. State Street Corp grew its position in shares of Merit Medical Systems by 1.5% in the 4th quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock valued at $196,645,000 after purchasing an additional 32,459 shares during the period. Conestoga Capital Advisors LLC raised its holdings in Merit Medical Systems by 3.9% during the 1st quarter. Conestoga Capital Advisors LLC now owns 2,167,513 shares of the medical instruments supplier’s stock worth $149,407,000 after buying an additional 81,030 shares during the period. Fuller & Thaler Asset Management Inc. lifted its stake in Merit Medical Systems by 12.7% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock valued at $183,137,000 after buying an additional 234,682 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Merit Medical Systems by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 1,327,013 shares of the medical instruments supplier’s stock valued at $116,963,000 after buying an additional 86,504 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Merit Medical Systems by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,237,298 shares of the medical instruments supplier’s stock valued at $85,287,000 after buying an additional 12,285 shares during the period. Institutional investors own 99.66% of the company’s stock.

Trending Headlines about Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 results exceeded expectations: Merit reported revenue of $418.8 million, up 9.5% year over year and above the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, beating estimates of $0.96; GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance
• Positive Sentiment: 2026 guidance was raised: Management now expects full-year adjusted EPS of $4.25-$4.35, above the $3.98 analyst consensus. Broad-based product growth, revenue gains and expanding margins supported the improved outlook. MMSI Q2 Earnings, Revenues Beat Estimates; 2026 Guidance Raised
• Positive Sentiment: Analyst targets moved higher: Needham raised its target to $101 and maintained a Buy rating; BTIG lifted its target to $105 and maintained Buy; and JPMorgan raised its target to $95 with an Overweight rating. These revisions indicate increased confidence in Merit’s growth and earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
• Neutral Sentiment: Analyst opinion remains mixed: Wells Fargo raised its target to $83 but retained an Equal Weight rating, leaving its target below the stock’s recent trading level. Wells Fargo Raises Merit Medical Price Target
• Negative Sentiment: Cash generation weakened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million, a potential concern despite the strong earnings performance. Merit Medical Second Quarter Results

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.